Cargando…

Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis

Fatty liver disease is a spectrum of liver pathologies ranging from simple hepatic steatosis to non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and culminating with the development of cirrhosis or hepatocellular carcinoma (HCC). The pathogenesis of NAFLD is complex a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Bing, Lu, Liqing, Zhou, Dongmei, Fan, Wei, Barbier-Torres, Lucía, Steggerda, Justin, Yang, Heping, Yang, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578007/
https://www.ncbi.nlm.nih.gov/pubmed/36267567
http://dx.doi.org/10.3389/fendo.2022.1007944
_version_ 1784811884550029312
author Yang, Bing
Lu, Liqing
Zhou, Dongmei
Fan, Wei
Barbier-Torres, Lucía
Steggerda, Justin
Yang, Heping
Yang, Xi
author_facet Yang, Bing
Lu, Liqing
Zhou, Dongmei
Fan, Wei
Barbier-Torres, Lucía
Steggerda, Justin
Yang, Heping
Yang, Xi
author_sort Yang, Bing
collection PubMed
description Fatty liver disease is a spectrum of liver pathologies ranging from simple hepatic steatosis to non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and culminating with the development of cirrhosis or hepatocellular carcinoma (HCC). The pathogenesis of NAFLD is complex and diverse, and there is a lack of effective treatment measures. In this review, we address hepatokines identified in the pathogenesis of NAFLD and NASH, including the signaling of FXR/RXR, PPARα/RXRα, adipogenesis, hepatic stellate cell activation/liver fibrosis, AMPK/NF-κB, and type 2 diabetes. We also highlight the interaction between hepatokines, and cytokines or peptides secreted from muscle (myokines), adipose tissue (adipokines), and hepatic stellate cells (stellakines) in response to certain nutritional and physical activity. Cytokines exert autocrine, paracrine, or endocrine effects on the pathogenesis of NAFLD and NASH. Characterizing signaling pathways and crosstalk amongst muscle, adipose tissue, hepatic stellate cells and other liver cells will enhance our understanding of interorgan communication and potentially serve to accelerate the development of treatments for NAFLD and NASH.
format Online
Article
Text
id pubmed-9578007
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95780072022-10-19 Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis Yang, Bing Lu, Liqing Zhou, Dongmei Fan, Wei Barbier-Torres, Lucía Steggerda, Justin Yang, Heping Yang, Xi Front Endocrinol (Lausanne) Endocrinology Fatty liver disease is a spectrum of liver pathologies ranging from simple hepatic steatosis to non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and culminating with the development of cirrhosis or hepatocellular carcinoma (HCC). The pathogenesis of NAFLD is complex and diverse, and there is a lack of effective treatment measures. In this review, we address hepatokines identified in the pathogenesis of NAFLD and NASH, including the signaling of FXR/RXR, PPARα/RXRα, adipogenesis, hepatic stellate cell activation/liver fibrosis, AMPK/NF-κB, and type 2 diabetes. We also highlight the interaction between hepatokines, and cytokines or peptides secreted from muscle (myokines), adipose tissue (adipokines), and hepatic stellate cells (stellakines) in response to certain nutritional and physical activity. Cytokines exert autocrine, paracrine, or endocrine effects on the pathogenesis of NAFLD and NASH. Characterizing signaling pathways and crosstalk amongst muscle, adipose tissue, hepatic stellate cells and other liver cells will enhance our understanding of interorgan communication and potentially serve to accelerate the development of treatments for NAFLD and NASH. Frontiers Media S.A. 2022-09-30 /pmc/articles/PMC9578007/ /pubmed/36267567 http://dx.doi.org/10.3389/fendo.2022.1007944 Text en Copyright © 2022 Yang, Lu, Zhou, Fan, Barbier-Torres, Steggerda, Yang and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Yang, Bing
Lu, Liqing
Zhou, Dongmei
Fan, Wei
Barbier-Torres, Lucía
Steggerda, Justin
Yang, Heping
Yang, Xi
Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
title Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
title_full Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
title_fullStr Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
title_full_unstemmed Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
title_short Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
title_sort regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9578007/
https://www.ncbi.nlm.nih.gov/pubmed/36267567
http://dx.doi.org/10.3389/fendo.2022.1007944
work_keys_str_mv AT yangbing regulatorynetworkandinterplayofhepatokinesstellakinesmyokinesandadipokinesinnonalcoholicfattyliverdiseasesandnonalcoholicsteatohepatitis
AT luliqing regulatorynetworkandinterplayofhepatokinesstellakinesmyokinesandadipokinesinnonalcoholicfattyliverdiseasesandnonalcoholicsteatohepatitis
AT zhoudongmei regulatorynetworkandinterplayofhepatokinesstellakinesmyokinesandadipokinesinnonalcoholicfattyliverdiseasesandnonalcoholicsteatohepatitis
AT fanwei regulatorynetworkandinterplayofhepatokinesstellakinesmyokinesandadipokinesinnonalcoholicfattyliverdiseasesandnonalcoholicsteatohepatitis
AT barbiertorreslucia regulatorynetworkandinterplayofhepatokinesstellakinesmyokinesandadipokinesinnonalcoholicfattyliverdiseasesandnonalcoholicsteatohepatitis
AT steggerdajustin regulatorynetworkandinterplayofhepatokinesstellakinesmyokinesandadipokinesinnonalcoholicfattyliverdiseasesandnonalcoholicsteatohepatitis
AT yangheping regulatorynetworkandinterplayofhepatokinesstellakinesmyokinesandadipokinesinnonalcoholicfattyliverdiseasesandnonalcoholicsteatohepatitis
AT yangxi regulatorynetworkandinterplayofhepatokinesstellakinesmyokinesandadipokinesinnonalcoholicfattyliverdiseasesandnonalcoholicsteatohepatitis